Cartesian Partners with WestGene to Advance In Vivo CAR-T Therapies for Autoimmune Diseases
Summary
Cartesian Therapeutics announced a strategic licensing agreement with WestGene Biopharma to develop novel in vivo CAR-T therapies for autoimmune diseases, with a Phase 1 clinical trial expected to start in 2H 2026.
Key Events
-
Strategic Licensing Agreement
Cartesian partnered with WestGene Biopharma to develop in vivo CAR-T therapies for autoimmune diseases.
-
Novel In Vivo Platform
The collaboration combines WestGene's targeted LNP platform with Cartesian's mRNA payloads to enable in vivo CAR-T generation, potentially eliminating ex vivo manufacturing.
-
Clinical Development Timeline
A Phase 1 dose-escalation study in myasthenia gravis is expected to begin in 2H 2026, with initial clinical data anticipated in 1H 2027.
-
Pipeline Expansion
The partnership aims to advance multiple next-generation anti-BCMA CAR constructs and a BCMA-directed T-cell engager, expanding Cartesian's mRNA payload portfolio.
Analysis
This strategic licensing agreement expands Cartesian's CAR-T platform into in vivo delivery, potentially streamlining manufacturing and accelerating clinical development. The partnership leverages WestGene's validated lipid nanoparticle (LNP) technology with Cartesian's mRNA payloads, aiming to initiate a Phase 1 study in myasthenia gravis in 2H 2026 with data expected in 1H 2027. This move is crucial for broadening Cartesian's pipeline and addressing a key challenge in cell therapy.
At the time of this filing, RNAC was trading at $6.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $172.2M. The 52-week trading range was $5.60 to $15.57. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.